99 related articles for article (PubMed ID: 14523941)
1. Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments.
Krauss U; Kratz F; Beck-Sickinger AG
J Mol Recognit; 2003; 16(5):280-7. PubMed ID: 14523941
[TBL] [Abstract][Full Text] [Related]
2. A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.
Orbán E; Manea M; Marquadt A; Bánóczi Z; Csík G; Fellinger E; Bosze S; Hudecz F
Bioconjug Chem; 2011 Oct; 22(10):2154-65. PubMed ID: 21950465
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin-derived peptide carriers: mechanisms and application.
Rennert R; Neundorf I; Beck-Sickinger AG
Adv Drug Deliv Rev; 2008 Mar; 60(4-5):485-98. PubMed ID: 18160173
[TBL] [Abstract][Full Text] [Related]
4. Cellular internalization of enhanced green fluorescent protein ligated to a human calcitonin-based carrier peptide.
Machova Z; Mühle C; Krauss U; Tréhin R; Koch A; Merkle HP; Beck-Sickinger AG
Chembiochem; 2002 Jul; 3(7):672-7. PubMed ID: 12325002
[TBL] [Abstract][Full Text] [Related]
5. Novel peptide conjugates for tumor-specific chemotherapy.
Langer M; Kratz F; Rothen-Rutishauser B; Wunderli-Allenspach H; Beck-Sickinger AG
J Med Chem; 2001 Apr; 44(9):1341-8. PubMed ID: 11311056
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity.
Rodrigues PC; Roth T; Fiebig HH; Unger C; Mülhaupt R; Kratz F
Bioorg Med Chem; 2006 Jun; 14(12):4110-7. PubMed ID: 16546396
[TBL] [Abstract][Full Text] [Related]
7. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.
Miklán Z; Orbán E; Csík G; Schlosser G; Magyar A; Hudecz F
Biopolymers; 2009; 92(6):489-501. PubMed ID: 19521976
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect.
Schlage P; Mezo G; Orbán E; Bosze S; Manea M
J Control Release; 2011 Dec; 156(2):170-8. PubMed ID: 21864594
[TBL] [Abstract][Full Text] [Related]
9. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
Orbán E; Mezo G; Schlage P; Csík G; Kulić Z; Ansorge P; Fellinger E; Möller HM; Manea M
Amino Acids; 2011 Jul; 41(2):469-83. PubMed ID: 20953647
[TBL] [Abstract][Full Text] [Related]
10. Generation of carrier peptides for the delivery of nucleic acid drugs in primary cells.
Rennert R; Neundorf I; Jahnke HG; Suchowerskyj P; Dournaud P; Robitzki A; Beck-Sickinger AG
ChemMedChem; 2008 Feb; 3(2):241-53. PubMed ID: 18205166
[TBL] [Abstract][Full Text] [Related]
11. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
van Zon A; Mossink MH; Schoester M; Scheper RJ; Sonneveld P; Wiemer EA
Cancer Res; 2004 Jul; 64(14):4887-92. PubMed ID: 15256459
[TBL] [Abstract][Full Text] [Related]
12. Structural investigations of a human calcitonin-derived carrier peptide in a membrane environment by solid-state NMR.
Wagner K; Beck-Sickinger AG; Huster D
Biochemistry; 2004 Oct; 43(39):12459-68. PubMed ID: 15449935
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin-derived carrier peptide plays a major role in the membrane localization of a peptide-cargo complex.
Boichot S; Krauss U; Plénat T; Rennert R; Milhiet PE; Beck-Sickinger A; Le Grimellec C
FEBS Lett; 2004 Jul; 569(1-3):346-50. PubMed ID: 15225660
[TBL] [Abstract][Full Text] [Related]
14. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape.
Foerg C; Ziegler U; Fernandez-Carneado J; Giralt E; Rennert R; Beck-Sickinger AG; Merkle HP
Biochemistry; 2005 Jan; 44(1):72-81. PubMed ID: 15628847
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells.
Noor F; Kinscherf R; Bonaterra GA; Walczak S; Wölfl S; Metzler-Nolte N
Chembiochem; 2009 Feb; 10(3):493-502. PubMed ID: 19115329
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and application of peptides as drug carriers.
Rennert R; Neundorf I; Beck-Sickinger AG
Methods Mol Biol; 2009; 535():389-403. PubMed ID: 19377983
[TBL] [Abstract][Full Text] [Related]
17. [Transportation of cytotoxic liposomes to malignant cells using a carbohydrate determinant].
Vodovozova EL; Khaĭdukov SV; Gaenko GP; Bondarchuk TN; Mikhalev II; Grechishnikova IV; Molotkovskiĭ IuG
Bioorg Khim; 1998 Oct; 24(10):760-7. PubMed ID: 9929737
[TBL] [Abstract][Full Text] [Related]
18. Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?
Lejeune A; Poyet P; Gaudreault RC; Gicquaud C
Anticancer Res; 1997; 17(5A):3599-603. PubMed ID: 9413209
[TBL] [Abstract][Full Text] [Related]
19. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin.
Lejeune A; Moorjani M; Gicquaud C; Lacroix J; Poyet P; Gaudreault R
Anticancer Res; 1994; 14(3A):915-9. PubMed ID: 8074493
[TBL] [Abstract][Full Text] [Related]
20. Nanoerythrosomes, a new derivative of erythrocyte ghost II: identification of the mechanism of action.
Moorjani M; Lejeune A; Gicquaud C; Lacroix J; Poyet P; Gaudreault RC
Anticancer Res; 1996; 16(5A):2831-6. PubMed ID: 8917393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
